The present study examined the acute effects of drugs that stimulate or block sympathetic nervous system activity on components of Type A behavior, affect, and cardiovascular responses to mental stressors. Either propranolol (a beta-adrenergic blocker), isoproterenol (a beta-agonist), or placebo was infused intravenously at different times in 12 healthy males. In two sessions, placebo (saline) was administered first, followed by a structured interview, challenging mental arithmetic test, and completion of affect scales. The procedure was then repeated with one of the active drugs, presented in counterbalanced order. Results indicated reliable drug effects on both heart rate (HR) and systolic blood pressure (SBP) reactivity to the tasks, with change scores to the tasks markedly increased by isoproterenol. Anxiety and hostility ratings paralleled results for HR and BP, with much of this effect being due to higher affect ratings for isoproterenol. The effect of the drugs on Type A behavior was unexpected, with global Type A and several components lowered by isoproterenol and unaffected by propranolol. These data are discussed in terms of the interfering effects of anxiety on Type A speech components. The influence of isoproterenol on affect and reactivity might reflect the physiologic action of a beta 2-adrenergic positive feedback loop which increases release of endogenous norepinephrine, and/or potentiating effects of emotion on reactivity to stress.
INTRODUCTION
The Type A behavior pattern and, more recently, physiologic responsiveness (reactivity) to stress have both been implicated as potential behavioral risk factors for cor-
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haviors be a cause of heightened physiologic responsiveness, but also some of these behaviors might reflect heightened sympathetic nervous system activity (5) . This idea is investigated by examining the behavioral effects of drugs that increase and decrease sympathetic nervous system activity. In the context of this study, the effects of these pharmacologic agents on cardiovascular reactivity to mental stressors are also examined.
The idea that certain Type A behaviors may reflect physiologic responsiveness is related to the notion that bodily activity can contribute to emotional experience (6) (7) (8) (9) . Several lines of evidence indicate that peripheral and/or central nervous system arousal can increase the intensity and quality of anger-related emotional affect and behavior (10) (11) (12) . This work is of relevance to the Type A construct since the component behaviors that define that Type A-vigorous vocal mannerisms, easily aroused anger, and impatience-may plausibly be viewed as a complex of interrelated emotional behaviors.
Support for this line of reasoning derives from studies of the effects of pharmacologic agents upon components of Type A behavior. If Type A behaviors are, in part, a reflection of sympathetic nervous system activity, the intensity of these behaviors should be reduced by beta-adrenergic blockade, which attenuates certain sympathetically mediated physiologic responses. This prediction was borne out in a correlational study (13) which indicated that structured interview (SI) ratings of coronary patients medicated with the betaadrenergic blocking drug propranolol showed lower levels of both global Type A behavior and specific components of Type A, including vigorous speech mannerisms and potential-for-hostility.
Similar results were obtained in two experimental studies comparing the effects upon Si-defined Type A behavior of other beta-blocking agents with the effects of other drugs that do not reduce cardiovascular reactivity. After receiving medications for 4-6 weeks, only patients treated with beta-blockers showed a decrease in intensity of Type A behavior and hostility, with this difference persisting for hostility after considerably longer follow-up periods (14) (15) (16) (17) . In two studies, these results were obtained with beta-blockers differing markedly in the extent to which they penetrate the CNS.
Taken together, these findings suggest that dampening of beta-adrenergically mediated responses produces a similar reduction in Type A behavior. However, this conclusion must be tempered by the correlational nature of one of the studies, and by the fact that none of the experimental studies included a placebo control group. In addition, it has not been shown that components of Type A behavior can be potentiated by any pharmacologic agent. The present line of reasoning would gain added support were it to be shown that aspects of Type A behavior are potentiated by acute administration of a drug such as isoproterenol which acts peripherally and increases beta-adrenergic activity, and diminished by acute administration of propranolol, which decreases beta-adrenergic responses.
In the context of studying the effects of sympathetic nervous system drugs on behavior, it is also of interest to examine the influence of these agents upon cardiovascular reactivity. Recently, there has been growing interest in modulators and stimulators of psychophysiologic responses to mental stressors (18) . Among the variables that have been studied are substances (e.g., caffeine and nicotine) that have actions at various sites, including the central and autonomic nervous systems, adrenergic receptors, and end-organs. The study of agents such as beta-adrenergic agonists and antagonists, whose pharmacologic effects are relatively specific, may shed light on physiologic mechanisms underlying certain substance-stress interactions. Moreover, as suggested earlier, agents affecting reactions to mental stressors also may operate through psychologic processes whereby the subject perceives and interprets bodily changes in a way that influences affective and behavioral responses.
Accordingly, we investigated the effects of a beta-adrenergic agonist, isoproterenol, and antagonist, propranolol. Of possible sympathetic agonists (e.g., epinephrine, norepinephrine), isoproterenol was chosen because it stimulates only beta receptors and, like the catecholamines, does not cross the blood-brain barrier. The two drugs, as well as placebo, were administered intravenously to study the role of sympathetically mediated cardiovascular activity in producing Type A behavior and affective responses to the SI and a difficult mental arithmetic task. In addition, we examined the effects of these drugs on cardiovascular reactivity to the mental stressors. It was expected that potentiation of cardiovascular activity with isoproterenol, and dampening of this activity with propranolol, would be accompanied by parallel changes in Type A behavior and in self-reported anger and anxiety. We also expected that propranolol would attenuate cardiovascular responses to mental stress, and that, perhaps, isoproterenol would increase heart rate and systolic blood pressure reactivity to mental stress.
METHODS

Subjects
Twelve healthy white males served as subjects. Their mean age was 24 years. These men were drawn from a pool of paid volunteers who were determined by history and physical and questionnaire examination to be free of pulmonary and cardiovascular disease, cardiac arrhythmias, and psychiatric disturbances.
Procedure
Subjects were tested twice in a counterbalanced, crossover design, with instructions not to take medications of any kind during the 3 days prior to each session-a period sufficient for elimination of agents such as antihistamines and analgesics. Prior to the session, subjects were informed that the purpose of the study was to determine if certain drugs could produce changes in ECG, blood pressure, and behavior, and informed consent was obtained. Subjects and interviewer were both blinded as to the order of drug administration, and the interviewer was generally unaware of the experimental hypotheses. In the first session, placebo (normal saline) was infused during a resting "baseline" period, during the SI (19) , and during a mental arithmetic (MA) task involving serial subtraction of either 13s or 17s out loud for 3 min. The experimenter mildly harassed the subjects to go faster and be more accurate during this task. The Structured Interview was begun approximately 10-15 min after the desired baseline dose of the drug was achieved. The MA task followed directly after the SI. Instructions for the mental arithmetic were given via audiotape, and the number to be subtracted was varied in a fixed order as different drugs were administered. To measure affective responses to the drugs and tasks, the subject then completed two wellvalidated mood/affect questionnaires: the Multiple Affect Adjective Checklist (MAACL; 20) and the state form of the State-Trait Personality Inventory (STPI; 21). This procedural sequence then was repeated with infusion of either isoproterenol or propranolol.
The second session took place about 2 months later. Procedures were identical to those of the first session, except that the placebo phase was followed by infusion of the other active drug. Subjects were assigned randomly to two groups, with one receiving isoproterenol in the first session and propranolol in BETA-ADRENERGIC STIMULATION AND BLOCKADE the second, and the other undergoing the reverse sequence. The study was designed with the placebo session always being first in each day because the long washout period for intravenous propranolol did not permit this drug to be administered first in a session.
Physiologic Recording
Heart rate (HR), scored from the ECG, was monitored continuously throughout both sessions. Systolic and diastolic blood pressure (SBP and DBP) were measured at 2-min intervals using a Parke-Davis microphone pick-up sphygmomanometer inflated remotely from an adjoining observation area. HR was recorded for the 30 sec preceding each BP measurement. Placebo baseline periods lasted 15 min, or longer if necessary, to permit heart rate and blood pressure to stabilize.
Baseline values for SBP and DBP were computed as the mean of the last two resting measurements for each drug condition. Heart rate baseline was the mean of the last 5 min of the baseline period. Heart rate and blood pressure values recorded during the SI and MA were averaged to produce a single value for each task during administration of each drug. The appropriate drug baseline value then was subtracted from each task value to generate change-scores reflecting reactivity to SI and-MA under each drug condition. Baselines and change-scores for the two placebo conditions were statistically identical and therefore were combined to generate a single set of placebo data.
Drug Administration
Both drugs were administered intravenously. The dose of propranolol was 0.2 mg/kg, administered in 3-mg boluses, each of which was infused over 2 min. Isoproterenol was administered at an increasing rate until a HR increase of about 10 bpm was produced (M = 11 bpm), at typically 1.0-1.5 (xg/min. The drug administration procedures were those utilized in previous research (22, 23) .
Assessment of Type A
Parallel but shortened forms of the SI were developed for repeated administration during each of the four drug conditions (Placebo-Session 1, Placebo-Session 2, Isoproterenol, and Propranolol). Each form comprised approximately equal numbers of questions pertaining to the various dimensions of Type A behavior, e.g., hostility, impatience, etc. The subject was led to believe that an interview would be given each testing day. In each session, a shortened interview was given by an experienced interviewer (J.A.) trained by Dr. Ray Rosenman. As the second drug of the day was started, the subject was told that the interview would be "continuing," and the second interview was given. The order of the interview forms was reversed for the second half of the subjects.
Type A behavior and components were rated by Dr. T. Dembroski, who has extensive experience with the technique, and who had no knowledge of the drugs administered in the study or the order of drug or placebo administration. Global Type A assessments were made using a 4-point scale, where Al = 4, A2 = 3, X = 2, and B = 1. In addition, 5-point ratings were made of the following component dimensions of Type A behavior: loudness, explosiveness, rapid and accelerated speech, short response latency, potential for hostility, and verbal competition (24) . The auditor rated the quality of each SI. Despite the somewhat shortened interviews, both interviewer and auditor felt them to be adequate in both length and quality to make accurate assessments of global Type A and components. The blinding of both interviewer and auditor, and the counterbalancing of drugs and order of interview forms, made it unlikely that interview characteristics would influence the results of the study. The study sample consisted of six Type A and six Type B subjects.
Data Analysis
The effect of drug administration upon resting cardiovascular activity was determined by conducting a series of one-way repeated-measures analyses of variance on the baseline values for HR, SBP, and DBP. Cardiovascular reactivity was analyzed by computing change-scores (mean task levels minus resting levels) for each cardiovascular variable, and submitting each variable to a repeated-measures (drug x task) analysis of variance. The six Type A component ratings, along with global Type A assessments, were submitted to a multivariate repeated-measures analysis of variance to assess the effects of drug administration. Similarly, MAACL anxiety and hostility scores, along with STPI anxiety and anger scores, were analyzed together in a multivariate repeatedmeasures analysis of variance.
Significant multivariate terms were followed by D. S. KRANTZ et al.
univariate F tests to determine the effects of drug administration upon individual dependent measures. Where univariate F tests revealed a significant main effect, post hoc analyses were carried out using the Newman-Keuls procedure (25) . Significant univariate interactions were followed by simple main effects analysis, using the appropriate error term and adjusted degrees of freedom (25) .
RESULTS
1
Effects of Drugs on Cardiovascular Baselines
Baseline HR values for each drug condition are depicted in Figure 1 . One-way analysis of variance yielded a significant drug effect, F(2/22) = 90.93, p < 0.0001. Post hoc comparisons indicated that propranolol HR baseline (M = 63.8 bpm) was reliably lower than placebo HR baseline (M = 77.0 bpm, p < 0.01), which, in turn, was reliably lower than isoproterenol HR baselines (M = 87.7 bpm, p < 0.01).
Baseline SBP values for each drug condition, presented in Figure 2 , were patterned in a manner similar to those for HR. Analysis of variance again produced a significant drug effect, F[2/22) = 22.78, p < 0.0001. Post hoc analysis revealed a reliable difference between SBP baselines for placebo and isoproterenol (Ms = 114.0 and 132.2 mm Hg, p < 0.01). However, SBP baselines for placebo and propranolol (M = 109.4 mm Hg) were not significantly different.
Drug administration also had a significant effect upon DBP baselines, F(2/22) = 42.48, p < 0.0001. Here, the pattern of differences was reversed, with baselines levels highest under propranolol, intermediate under placebo, and lowest under isoproterenol (Ms were 76.0, 67.8, and 48.0 mm Hg, ps < 0.05). This result is due to the fact that peripheral beta-2 receptors when stimulated have a vasodilatory effect in the peripheral vasculature.
Cardiovascular Change-Scores
Effects of Drug and Task. Analysis of HR change-scores revealed a significant drug effect, F(2/22) = 10.34, p < 0.001, task effect, F(l/ll) = 13.53, p < 0.01, and drug X task interaction, F(2/22) = 9.61, p < 0.01. As can be seen in Figure 1 , the modest HR elevations occuring during both tasks under placebo conditions were virtually eliminated by infusion of propranolol. The effect of isoproterenol administration was to increase change-scores to both tasks relative to those seen under placebo. This pattern was more pronounced in the HR data for MA than for the SI, which accounts for the significant interaction.
Simple effects tests indicated that the impact of drug administration on HR was statistically reliable for MA, F(2/31) = 17.66, p < 0.0001, but only marginal for the SI, F(2/31) = 2.76, p = 0.08. Post hoc analysis of the MA data showed that means for both isoproterenol (M = +14.0 bpm) and propranolol (M = 0.0 bpm) differed significantly from those for placebo (M = + 6.8) at p < 0.01.
The upper portion of Table 1 summarizes the HR reactivity results for individual subjects. During MA, 10 of 12 subjects had lower HR change-scores under propranolol compared to placebo, and the same proportion had greater HR change-scores for isoproterenol compared to placebo. Corresponding proportions for the SI were 7 of 12 and 8 of 12.
Analysis of SBP change-scores, which are depicted in Figure 2 significantly higher than those for placebo (Ms = + 29.6 and +16.4 mm Hg, p < 0.01). The difference between change-scores for propranolol (M = +8.9 mm Hg) and placebo fell just short of significance at p = 0.06. The absence of an interaction indicates that the tendency for drug effects to be stronger for MA than for the SI (see Fig.  2 ) was not statistically reliable.
The lower portion of Table 1 summarizes the SBP reactivity data for individual subjects. Change-scores under isoproterenol were greater than placebo values for 11 of the 12 during both tasks. The proportion of subjects showing lower SBP change-scores under propranolol compared to placebo was 10 of 12 for the SI and 9 of 12 for MA.
The DBP data yielded only a significant drug effect [F(2/22) = 4.30, p < 0.05]. This term reflected lower DBP change scores for isoproterenol compared to placebo (Ms = D. S. KRANTZetal.
-1.4 and + 8.6 ram Hg, p < 0.05). Changescores for propranolol (M = + 6.5 mm Hg) were intermediate in magnitude and did not differ reliably from either of the other treatment means. Both the task effect and drug x task interaction failed to approach significance (ps > 0.14).
Effects of Type A behavior. Changescores for SBP, DBP, and HR were reanalyzed in a series of Type A/B x drug x task analyses of variance, using SI ratings from the Session 1 placebo condition for behavior pattern classification. Results for SBP and HR replicated the drug and task effects described above, but none of the terms involving Type A behavior ap- Under placebo, DBP change-scores for Type Bs were somewhat higher than those for Type As (Ms = +12.0 and +5.2 mm Hg). This difference was smaller in the propranolol condition (Ms = +7.4 and +5.6mmHg), and considerably larger in the isoproterenol condition, in which DBP change-scores for Type As declined precipitously (Ms = + 7.9 and -10.8 mm Hg).
Effects of Drug on Type A Behaviors
Multivariate analysis of the Type A data yielded a reliable term for the drug effect [Wilks'lambda = 0.2054, F(14/32) = 2.76, p < 0.01]. As can be seen in Table 2 , significant or near-significant univariate drug effects were obtained for four Type A variables, these being rapid/accelerated speech, potential for hostility, verbal competition, and global Type A. Contrary to expectations, scores on these variables were lower for isoproterenol than for placebo, with this difference attaining significance (ps < 0.05) for three of the four measures, the exception being hostility (see Table 2 ). Also unexpected is the similarity between scores for propranolol and placebo, which are nearly identical, except in the case of hostility, where propranolol ratings nonsignificantly exceeded those for placebo.
Effects of Drugs on Affect Ratings
Multivariate analysis of the affect ratings also produced a statistically significant drug effect [Wilks' lambda = 0.3201, F(8/38) = 3.65, p < 0.01]. Univariate analysis yielded significant drug terms for each scale (ps < 0.05], Cell means are presented in Table 3 . Post hoc comparisons revealed that for each measure, isoproterenol ratings were reliably higher than those for placebo (ps < 0.05), with no significant differences between placebo and propranolol.
Other Relevant Data
Since isoproterenol infusion was associated with both a reduction in Type A behavior and an increase in reported negative affect, it is of interest to determine whether these represent independent or correlated effects of the drug. Consequently, change-scores were computed to reflect the impact of isoproterenol on these variables, using mean placebo scores as a baseline.
Correlations between the two sets of scores revealed that most of the coefficients were negative, with many of these inverse associations of moderate to high magnitude. For example, after isoproterenol, respective correlations with loud speech, explosiveness, rapid/accelerated, short response latency, potential-for-hostility, verbal competition, and global Type A were -0.54, -0.58, -0.30, -0.33, -0.12, +0.14, and -0.55 for MAACL anxiety ratings. For STPI anger ratings correlations with these Type A components derived from the SI were -0.44, -0.06, -0.61, -0.60, -0.57, -0.45, and -0.36, respectively. These results suggested that subjects showing reductions in Si-defined Type A behavior as a result of isoproterenol infusion showed concomitant increases in reported self-rated anxiety and anger.
DISCUSSION
The effects of the drugs on cardiovascular baseline and reactivity measures were generally as expected. Propranolol vir-tually eliminated HR responses to both the SI and MA, and produced a 7-mm Hg reduction in SBP responses to these tasks. Change-scores for DBP were unaffected by beta-blockade. Of greater interest, isoproterenol potentiated HR and SBP responses to both tasks. That is, reactivity was greater under isoproterenol than for placebo, despite the fact that change-scores in the former condition were computed from HR and SBP baselines that already were elevated due to infusion of isoproterenol while subjects were at rest. For DBP, isoproterenol infusion had the effect of blunting reactivity to the two stressors.
The enhancement of stress-reactivity of HR and SBP might reflect the operation of a positive feedback loop involving presynaptic beta-2 receptors at sympathetic nerve endings. Stimulation of these receptors by beta-2 agonists increases release of norepinephrine (26, 27) . By activating this mechanism, isoproterenol-a potent agonist at both beta-1 and beta-2 receptorsmight increase synaptic norepinephrine output and result in greater cardiovascular responses than were produced by the mental stressors alone. The effect of isoproterenol on DBP reactivity is not surprising, since there is a vasodilatory effect of beta-2 stimulation that offsets the increase in vascular tone otherwise produced by stressreleased endogenous catecholamines.
In contrast to the cardiovascular measures, structured interview derived measures of Type A behavior responded to drug administration in an unexpected manner. Propranolol had no effect on any of the Type A measures, whereas isoproterenol significantly reduced rapid and accelerated speech, verbal competition, and global Type A ratings. Subjects' self-ratings of affect, however, conformed more closely to initial expectations. Isoproterenol significantly elevated reported anxiety, hostility, and anger, as was anticipated on the basis of somatopsychic theories of emotion (6) . However, propranolol did not reduce reported negative affect, and was associated with ratings that were nearly identical to those given under placebo.
Results for the affect ratings under isoproterenol can be explained in terms of the effects of that drug on peripheral autonomic responses. Subjects no doubt became aware of the marked increases in heart rate and tremor, and consequently may have perceived themselves as more anxious and angry. This conclusion would have been strengthened had the extent to which subjects perceived somatic changes been assessed directly. However, such questionning about bodily states can often have the undesired effect of focusing subjects' attention on their bodily reactions. The lack of effect of propranolol on rated affect could conceivably be due to the fact that under normal conditions (i.e., placebo or no drug), peripheral sympathetic responses do not contribute to heightened stress or anxiety during the structured interview and mental arithmetic. Indeed, a review of the literature on the behavioral effects of betablockers (28) suggests that these drugs are only effective in reducing anxiety in those situations (e.g., public speaking or performing before an audience) in which peripheral physiologic symptoms heighten the experience of anxiety.
More difficult to explain are the effects of the drugs on SI measures of Type A. It will be recalled that predictions based on the psychobiologic model of Krantz and Durel (5) called for reductions in Type A behavior under propranolol, and increases under isoproterenol. Regarding this hypothesis, these data suggest two possible conclusions. One is that the concept of elements of Type A reflecting heightened sympathetic reactivity is not correct. How-ever, before this hypothesis is abandoned it is necessary to account for a supporting body of data that has been obtained in hypertensive and coronary patient samples (13) (14) (15) (16) (17) .
Alternatively, our acute intravenous drug infusion paradigm may not be a satisfactory one for testing the psychobiologic model. It was our impression during the study that we were placing the subjects, with intravenous lines and ECG leads attached, in a restrained, passive situation. If this were so, they may have been constrained from responding to the situation in an aggressive Type A manner. Also of relevance here are the particular physiologic effects of intravenous isoproterenol, compared to the effects of other possible sympathetic agonist drugs that could have been utilized (e.g., epinephrine or norepinephrine). When infused in humans, isoproterenol and epinephrine result in markedly increased HR and SBP, and decreased DBP (29) . By contrast, exogenous norepinephrine produces increased SBP and DBP, with little increase, or even a decrease in HR. In addition to physiologic effects similar to those of epinephrine, isoproterenol may produce similar psychologic effects. For example, when administered to patients with respiratory difficulties, epinephrine commonly produces feelings of anxiety, fear, or tenseness (29) . Norepinephrine infusion has fewer and less pronounced effects.
It is conceivable, therefore, that the tachycardia and tremor produced by isoproterenol resulted in the perceptions of anxiety that are incompatible with Type A speech stylistics, and that norepinephrine would not have produced such effects. Indeed, in a review of the effects of anxiety on speech tempo, Siegman (30) found evidence of an inverted-U relationship, with speech rate increasing with moderate anxiety and decreasing with intense anxiety. Since anxiety ratings appear to have been increased markedly in the present study, it is possible that this emotion acted to decrease the Si-assessed speech characteristics as well. An affectinterference explanation of the Type A data is supported by the several sizable negative correlations that were found between isoproterenol-induced changes in Type A components and changes in anxiety and anger.
Evidence from other sources is at least consistent with the notion that intense anxiety and, perhaps, the self-report of anger, are orthogonal to overtly observed Type A components of the SI. Matthews et al. (31) found in factor analyzing the SI components that speech stylistics were relatively independent of an anger factor consisting of self-reported impatience and irritability. In addition, studies correlating the SI with measures of self-reported affect typically reveal little relationship between these variables (32) .
The present study did not find that Type A subjects showed greater cardiovascular reactivity than their Type B counterparts. It is possible to propose that the passive, restrained situation of drug infusion also acted against obtaining such a relationship, since Type A subjects may have been restricted from their usual manner of coping with the tasks. Although we are unable to offer a further explanation for these results from the data available, this study is one of several that suggest that the relationship between Type A and reactivity is far more complex than it initially appeared to be (3, 4) .
Also to be explained is the lack of an effect of acute infusion of propranolol on Type A. It should first be noted that studies that have reported an effect of betablockers in reducing Type A have utilized samples of hypertensives and coronary patients (13) (14) (15) (16) (17) . By contrast, subjects in the present study were healthy young males. Differences in the metabolism of oral versus intravenous propranolol could also account for the results obtained in this study (29, 33) , and it is possible that the Type A-reducing effect of the drug is confined to chronic, long-term oral administration. More specifically, there is no "first pass" metabolism by the liver of intravenously administered propranolol and an absence of some major active active metabolites of the drug (e.g., 4-OH-propranolol) (33) . There is additional evidence of a lack of a correlation between the antiarrhythmic efficacy of intravenous and oral propranolol (34) , and that chronic oral therapy may involve intracellular effects that are accomplished more slowly than the receptor blockade during acute administration (33, 35) . On the other hand, since there were no A-B differences in reactivity in the present study and since the SI elicited a rather small HR increase during placebo, conditions may not have been conducive to testing the hypothesis that a reduction in reactivity would diminish Type A behavior.
Perhaps the results of greatest interest in this study are those for isoproterenol, which strongly potentiated HR and SBP reactivity, as well as negative affective responses, to both stressors. We have already considered a possible physiologic explanation for these findings involving the effects of presynaptic beta-2 receptors. An alternative interpretation is that the SI and MA were perceived as more stressful under conditions of isoproterenol-induced sympathetic activity, thereby producing still greater reactivity to the stressors. As described earlier, such an interpretation proposes that perception of sympathetic responses heightens further the psychophysiologic reactivity to stressors.
The present data do not permit a determination of the relative contribution of psychologic versus physiologic mechanisms in potentiating cardiovascular reactivity. Resolution of this issue requires further investigations that either manipulate emotional arousal without stimulating beta-2 receptors, or stimulate beta-2 receptors without increasing emotional arousal. For example, if a selective beta-2 agonist (e.g., terbutaline) increased reactivity to stress without increasing emotional arousal, this would support a physiologic explanation for this effect. Such an explanation would also be supported if during stress periods with isoproterenol, there was a proportionally greater rise in the ratio of plasma norepinephrine/epinephrine than during stress periods with placebo. Either the beta-2 adrenergic feedback loop or the somatopsychic mechanism could be of relevance in understanding interactions of stress-induced reactivity with emotional affect and substances influencing the sympathetic nervous system.
